undamentalytics Newsletter
Sign in

Tonix Pharmaceuticals Holding Corp. income statement

In fiscal 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $13.1m, up 29.8% on the year before, operating income of −$126m (a -959.1% margin) and net income of −$124m, or −$14.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8101329
Cost of revenue5875
Gross profit32624
Research and development87404464
Selling, general and administrative354088126
Operating income−118−137−126−165
Interest expense—10—
Provision for credit losses——0—
Net income−117−130−124−160
Diluted EPS−$14720.25−$176.60−$14.57—
Diluted shares (average)——9m—
EBITDA−114−133−124−163

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARCT vs TNXPGLUE vs TNXPSTOK vs TNXP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tonix Pharmaceuticals Holding Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tonix Pharmaceuticals Holding Corp.